HSPD1 and stiff-person syndrome: This article proposes that MAP provides the immunogen HSP65; further, the article proposes the treatment of both MAP and the inflammatory manifestations of SPS with BEA, a therapeutic agent that can treat inflammation and mycobacterial infection [83,84].